Stoke director granted options for 17,786 shares

Stoke Therapeutics director Arthur A. Levin received a grant of stock options covering 17,786 shares of common stock.

Rhea-AI Filing Summary

Stoke Therapeutics director Arthur A. Levin received a grant of stock options covering 17,786 shares of common stock. The options have an exercise price of $29.46 per share and expire on June 2, 2036. According to the grant terms, the award vests in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, contingent on Levin’s continued service.

Insider Trade Summary

Grant/Award: 17,786 shares

Grant/Award 1 txn

Insider LEVIN ARTHUR A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	17,786	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 17,786 contracts (Direct)

Footnotes (1)

1. F1. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

Key Figures

Option grant size: 17,786 shares Exercise price: $29.46/share Shares after transaction: 17,786 derivatives +2 more

5 metrics

Option grant size 17,786 shares Director stock option award to Arthur A. Levin

Exercise price $29.46/share Strike price for director stock option

Shares after transaction 17,786 derivatives Total option shares held following this grant

Expiration date June 2, 2036 Option term end for director grant

Vesting date trigger June 3, 2027 Latest vesting date, or earlier at next annual meeting

Key Terms

Director Stock Option, exercise price, vesting, expiration date

4 terms

Director Stock Option financial

"security_title: "Director Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "29.4600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-06-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Stoke Therapeutics (STOK) director Arthur Levin report on this Form 4?

Arthur Levin reported receiving a grant of stock options for 17,786 shares of Stoke Therapeutics common stock. These options were awarded as director compensation, giving him the right to buy shares at a fixed price if the vesting conditions are met.

How many Stoke Therapeutics (STOK) shares are covered by Arthur Levin’s new stock options?

The new director stock option grant covers 17,786 shares of Stoke Therapeutics common stock. This entire amount represents Levin’s option position reported in this filing following the transaction, reflecting the size of this specific equity award.

What is the exercise price of Arthur Levin’s Stoke Therapeutics (STOK) stock options?

The options have an exercise price of $29.46 per share. This means Levin can buy up to 17,786 shares of Stoke Therapeutics common stock at $29.46, once the award is vested and before the options expire if he chooses to exercise.

When do Arthur Levin’s Stoke Therapeutics (STOK) stock options vest?

The option vests in full on the earlier of June 3, 2027 or the date of Stoke Therapeutics’ next annual stockholder meeting. Vesting is conditioned on Levin’s continued service to the company through that vesting date, as disclosed in the footnote.

What is the expiration date of Arthur Levin’s Stoke Therapeutics (STOK) option grant?

The director stock option expires on June 2, 2036. After that date, Levin can no longer exercise the option to purchase shares, even if it has vested and was not previously exercised during the option term.

Is Arthur Levin’s Form 4 transaction a purchase or a grant of Stoke Therapeutics (STOK) options?

The Form 4 reports a grant of stock options, not an open-market purchase. The transaction code is “A,” described as a grant, award, or other acquisition, and the price per option at grant is shown as $0.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEVIN ARTHUR A

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$29.46	06/03/2026		A		17,786		(1)	06/02/2036	Common Stock	17,786	$0	17,786	D

Explanation of Responses:

1. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)